AR123908A2 - Proteínas de fusión para tratar trastorno metabólicos - Google Patents
Proteínas de fusión para tratar trastorno metabólicosInfo
- Publication number
- AR123908A2 AR123908A2 ARP210102949A ARP210102949A AR123908A2 AR 123908 A2 AR123908 A2 AR 123908A2 AR P210102949 A ARP210102949 A AR P210102949A AR P210102949 A ARP210102949 A AR P210102949A AR 123908 A2 AR123908 A2 AR 123908A2
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- fusion protein
- fgf21
- metabolic disorders
- fusion proteins
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factors [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
La invención se refiere a la identificación de proteínas de fusión que comprenden variantes polipeptídicas y proteicos del factor de crecimiento de fibroblastos 21 (FGF21) que tienen propiedades farmacéuticas mejoradas. También se describen métodos para el tratamiento de trastornos asociados con el FGF21, incluyendo trastornos metabólicos. Reivindicación 1: Una proteína de fusión caracterizada porque comprende una variante de FGF21 y una región Fc, en donde la secuencia de aminoácidos de la proteína de fusión es SEQ ID Nº 10, SEQ ID Nº 11, SEQ ID Nº 12, o SEQ ID Nº 13. Reivindicación 3: La proteína de fusión de la Reivindicación 1 o Reivindicación 2, caracterizada porque comprende al menos un enlace disulfuro diseñado entre Gln55Cys y un residuo de cisteína en uno de Cys103, Cys121, Gly148Cys, Asn149Cys, Ser151Cys, Pro152Cys, His153Cys, Arg154Cys, Asp155Cys, Pro156Cys, Ala157Cys, Arg159Cys, Gly160Cys, Pro161Cys, Ala162Cys y Arg163Cys. Reivindicación 4: La proteína de fusión de la Reivindicación 1 o Reivindicación 2, caracterizada porque comprende al menos un enlace disulfuro diseñado entre Gly148Cys y un residuo de cisteína en uno de Cys103, Cys121, Arg47Cys, Tyr48Cys, Leu49Cys, Tyr50Cys, Thr51Cys, Asp52Cys, Asp53Cys, Ala54Cys, Gln55Cys, Gln56Cys, Thr57Cys, Glu58Cys, Gly160Cys, Pro161Cys, Ala162Cys, Arg163Cys y Phe164Cys.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161539280P | 2011-09-26 | 2011-09-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR123908A2 true AR123908A2 (es) | 2023-01-25 |
Family
ID=46970456
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120103553 AR088044A1 (es) | 2011-09-26 | 2012-09-26 | Proteinas de fusion para tratar trastornos metabolicos |
ARP210102949A AR123908A2 (es) | 2011-09-26 | 2021-10-25 | Proteínas de fusión para tratar trastorno metabólicos |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120103553 AR088044A1 (es) | 2011-09-26 | 2012-09-26 | Proteinas de fusion para tratar trastornos metabolicos |
Country Status (41)
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101400105B1 (ko) | 2006-07-25 | 2014-06-19 | 리폭센 테크놀로지즈 리미티드 | N-말단 폴리시알화 |
KR101476472B1 (ko) | 2007-03-30 | 2015-01-05 | 암브룩스, 인코포레이티드 | 변형된 fgf-21 폴리펩티드 및 그 용도 |
EP2600901B1 (en) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
ES2737960T3 (es) | 2010-10-01 | 2020-01-17 | Modernatx Inc | Nucleósidos, nucleótidos y ácidos nucleicos modificados y sus usos |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
SG10201806648TA (en) | 2011-07-01 | 2018-09-27 | Ngm Biopharmaceuticals Inc | Compositions, uses and methods for treatment of metabolic disorders and diseases |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
UY34346A (es) | 2011-09-26 | 2013-04-30 | Novartis Ag | Proteínas de fusión para tratar trastornos metabólicos |
TW201315742A (zh) | 2011-09-26 | 2013-04-16 | Novartis Ag | 治療代謝病症之雙功能蛋白質 |
EP3682905B1 (en) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
EP2791160B1 (en) | 2011-12-16 | 2022-03-02 | ModernaTX, Inc. | Modified mrna compositions |
AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
EP4074834A1 (en) | 2012-11-26 | 2022-10-19 | ModernaTX, Inc. | Terminally modified rna |
US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
US9963494B2 (en) | 2012-11-28 | 2018-05-08 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF19 polypeptides for reducing glucose levels in a subject |
CN105008548B (zh) | 2012-12-27 | 2020-11-27 | 恩格姆生物制药公司 | 用于调节胆汁酸体内稳态以及治疗胆汁酸紊乱和疾病的方法 |
US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
CA2926218A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
WO2015057908A1 (en) | 2013-10-18 | 2015-04-23 | Novartis Ag | Methods of treating diabetes and related disorders |
MX2016004822A (es) | 2013-10-28 | 2016-08-17 | Ngm Biopharmaceuticals Inc | Modelos de cancer y metodos asociados. |
LT3097122T (lt) | 2014-01-24 | 2020-07-27 | Ngm Biopharmaceuticals, Inc. | Antikūnai, surišantys beta kloto domeną 2, ir jų panaudojimo būdai |
JP6712230B2 (ja) | 2014-03-11 | 2020-06-17 | ノバルティス アーゲー | リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法 |
US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
CA2951153A1 (en) | 2014-06-16 | 2015-12-23 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
IL251834B2 (en) * | 2014-10-23 | 2023-09-01 | Ngm Biopharmaceuticals Inc | Pharmaceutical compositions containing peptide variants and methods of using them |
KR102637699B1 (ko) | 2014-10-24 | 2024-02-19 | 브리스톨-마이어스 스큅 컴퍼니 | 변형된 fgf-21 폴리펩티드 및 그의 용도 |
WO2016073855A1 (en) | 2014-11-07 | 2016-05-12 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
KR20160088656A (ko) | 2015-01-16 | 2016-07-26 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
US11236159B2 (en) | 2015-08-03 | 2022-02-01 | Novartis Ag | Methods of treating FGF21-associated disorders |
CA3003616C (en) | 2015-11-09 | 2020-07-28 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
TW201731867A (zh) * | 2015-12-02 | 2017-09-16 | 賽諾菲公司 | Fgf21變異體 |
CN117535350A (zh) * | 2016-05-20 | 2024-02-09 | 哈佛学院董事及会员团体 | 年龄相关疾病和病症的基因治疗方法 |
MX2018014475A (es) | 2016-05-25 | 2019-05-23 | Univ Texas | Métodos y composiciones para el tratamiento de trastornos secretorios. |
US11123438B2 (en) | 2016-08-19 | 2021-09-21 | Ampsource Biopharma Shanghai Inc. | Linker peptide for constructing fusion protein |
CN107759696A (zh) | 2016-08-19 | 2018-03-06 | 安源医药科技(上海)有限公司 | 人白介素7融合蛋白及其制备方法 |
CN106279437B (zh) | 2016-08-19 | 2017-10-31 | 安源医药科技(上海)有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
AU2017315459B2 (en) | 2016-08-26 | 2023-06-29 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
EP3558341A1 (en) | 2016-12-22 | 2019-10-30 | Sanofi | Fgf21 compound / glp-1r agonist combinations with optimized activity ratio |
US20220127322A1 (en) * | 2017-03-14 | 2022-04-28 | Sunshine Lake Pharma Co., Ltd. | Dual-target fusion proteins comprising the fc portion of an immunoglobulin |
CN107050429B (zh) * | 2017-04-01 | 2020-12-15 | 杭州生物医药创新研究中心 | 人成纤维生长因子21在制备用于治疗脑卒中药物中的应用 |
CA3062473A1 (en) | 2017-05-05 | 2018-11-08 | Trefoil Therapeutics, Inc. | Recombinant modified fibroblast growth factors and therapeutic uses thereof |
CN115109166A (zh) * | 2017-11-24 | 2022-09-27 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的多结构域活性蛋白 |
WO2019119673A1 (zh) | 2017-12-19 | 2019-06-27 | 北京吉源生物科技有限公司 | 一种双基因修饰的干细胞及其用途 |
IL307483A (en) * | 2017-12-22 | 2023-12-01 | Novartis Ag | Methods for treating metabolic disorders with FGF21 variants |
US11679143B2 (en) | 2018-02-08 | 2023-06-20 | Sunshine Lake Pharma Co., Ltd. | FGF21 variant, fusion protein and application thereof |
PE20210632A1 (es) | 2018-07-03 | 2021-03-23 | Bristol Myers Squibb Co | Formulaciones de fgf-21 |
CN111195234B (zh) * | 2018-11-16 | 2022-08-26 | 鲁南制药集团股份有限公司 | 一种重组FGF21-Fc融合蛋白冻干粉制剂 |
EP3736574A1 (en) * | 2019-05-07 | 2020-11-11 | Atlas Antibodies AB | A formulation comprising an isotope labeled fusion polypeptide |
CN111944055B (zh) | 2019-05-16 | 2022-08-02 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的融合蛋白 |
CN112386575B (zh) * | 2019-08-19 | 2023-03-21 | 鲁南制药集团股份有限公司 | 一种代谢调节融合蛋白的冻干制剂 |
AU2020345943A1 (en) | 2019-09-10 | 2022-03-31 | Obsidian Therapeutics, Inc. | CA2-IL15 fusion proteins for tunable regulation |
TW202135811A (zh) | 2019-12-20 | 2021-10-01 | 瑞士商諾華公司 | 使用整聯蛋白抑制劑組合治療肝臟疾病 |
JP6924291B2 (ja) | 2020-01-21 | 2021-08-25 | シャープ株式会社 | 端末装置、方法、および、集積回路 |
WO2022101853A1 (en) | 2020-11-16 | 2022-05-19 | Novartis Ag | Method of determining liver fibrosis |
CN113265007B (zh) * | 2021-06-10 | 2022-02-15 | 江南大学 | 一种治疗代谢疾病的融合蛋白及其制备方法和应用 |
WO2023245543A1 (en) * | 2022-06-23 | 2023-12-28 | Ampsource Biopharma Shanghai Inc. | Uses of fgf21 fusion proteins |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
US4615885A (en) | 1983-11-01 | 1986-10-07 | Terumo Kabushiki Kaisha | Pharmaceutical composition containing urokinase |
EP0315456B1 (en) | 1987-11-05 | 1994-06-01 | Hybritech Incorporated | Polysaccharide-modified immunoglobulins having reduced immunogenic potential or improved pharmacokinetics |
US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
US5234784A (en) | 1992-04-01 | 1993-08-10 | Eastman Kodak Company | Method of making a projection viewable transparency comprising an electrostatographic toner image |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
PT1232264E (pt) | 1999-11-18 | 2009-11-26 | Novartis Vaccines & Diagnostic | Gene fgf-21 humano e produtos da expressão do gene |
US6716626B1 (en) | 1999-11-18 | 2004-04-06 | Chiron Corporation | Human FGF-21 nucleic acids |
DK1616575T3 (da) | 1999-12-23 | 2012-09-10 | Zymogenetics Inc | Fremgangsmåde til behandling af inflammation |
US20040259780A1 (en) | 2001-07-30 | 2004-12-23 | Glasebrook Andrew Lawrence | Method for treating diabetes and obesity |
CA2545539A1 (en) | 2003-10-15 | 2005-04-28 | Pdl Biopharma, Inc. | Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig |
KR20060135648A (ko) * | 2003-12-10 | 2006-12-29 | 일라이 릴리 앤드 캄파니 | 섬유모세포 성장인자 21의 뮤테인 |
SI1751184T1 (sl) * | 2004-05-13 | 2010-01-29 | Lilly Co Eli | Fgf-21 fuzijski proteini |
DE602005016946D1 (de) * | 2004-09-02 | 2009-11-12 | Lilly Co Eli | Muteine des fibroblasten-wachstumsfaktors 21 |
US20080261875A1 (en) | 2005-01-21 | 2008-10-23 | Eli Lilly And Company | Method For Treating Cardiovascular Disease |
JOP20190083A1 (ar) * | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
BRPI0919932A8 (pt) | 2008-10-24 | 2018-02-06 | Novartis Ag | Pirrolina-carbóxi-lisina gerada biossinteticamente, bem como processo para preparar método para derivatizar uma proteína |
US20120052069A1 (en) * | 2009-05-05 | 2012-03-01 | Amgen Inc | Fgf21 mutants and uses thereof |
CN107188950B (zh) * | 2009-05-05 | 2021-09-28 | 安姆根有限公司 | Fgf21突变体及其用途 |
CA2764835A1 (en) * | 2009-06-17 | 2010-12-23 | Amgen Inc. | Chimeric fgf19 polypeptides and uses thereof |
KR20120107122A (ko) | 2009-12-22 | 2012-09-28 | 노파르티스 아게 | 치료법에서 사용하기 위한 4가 cd47―항체 불변 영역 융합 단백질 |
DE102010038140B4 (de) * | 2010-10-13 | 2020-06-18 | Hettich-Heinze Gmbh & Co. Kg | Beschlag für eine Schiebetür |
US9023791B2 (en) | 2010-11-19 | 2015-05-05 | Novartis Ag | Fibroblast growth factor 21 mutations |
TW201315742A (zh) * | 2011-09-26 | 2013-04-16 | Novartis Ag | 治療代謝病症之雙功能蛋白質 |
UY34346A (es) * | 2011-09-26 | 2013-04-30 | Novartis Ag | Proteínas de fusión para tratar trastornos metabólicos |
JP6712230B2 (ja) | 2014-03-11 | 2020-06-17 | ノバルティス アーゲー | リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法 |
-
2012
- 2012-09-25 UY UY34346A patent/UY34346A/es active IP Right Grant
- 2012-09-25 US US13/626,194 patent/US9006400B2/en active Active
- 2012-09-25 TW TW101135183A patent/TWI593708B/zh active
- 2012-09-25 JO JOP/2012/0279A patent/JO3476B1/ar active
- 2012-09-26 CA CA2849464A patent/CA2849464C/en active Active
- 2012-09-26 HR HRP20211575TT patent/HRP20211575T1/hr unknown
- 2012-09-26 EA EA201490695A patent/EA039633B1/ru unknown
- 2012-09-26 MY MYPI2014700650A patent/MY166059A/en unknown
- 2012-09-26 DK DK12768999.0T patent/DK2760475T3/en active
- 2012-09-26 EP EP12768999.0A patent/EP2760475B1/en active Active
- 2012-09-26 KR KR1020147010946A patent/KR102085605B1/ko active IP Right Grant
- 2012-09-26 AR ARP120103553 patent/AR088044A1/es active IP Right Grant
- 2012-09-26 SG SG10201602339XA patent/SG10201602339XA/en unknown
- 2012-09-26 ES ES12768999.0T patent/ES2689762T3/es active Active
- 2012-09-26 LT LTEP12768999.0T patent/LT2760475T/lt unknown
- 2012-09-26 EP EP17201957.2A patent/EP3321276B1/en active Active
- 2012-09-26 DK DK17201957.2T patent/DK3321276T3/da active
- 2012-09-26 RS RS20211120A patent/RS62341B1/sr unknown
- 2012-09-26 WO PCT/US2012/057384 patent/WO2013049247A1/en active Application Filing
- 2012-09-26 LT LTEP17201957.2T patent/LT3321276T/lt unknown
- 2012-09-26 CN CN201710255835.5A patent/CN107266579B/zh active Active
- 2012-09-26 JP JP2014532117A patent/JP6186361B2/ja active Active
- 2012-09-26 HU HUE17201957A patent/HUE055584T2/hu unknown
- 2012-09-26 PT PT17201957T patent/PT3321276T/pt unknown
- 2012-09-26 PE PE2014000418A patent/PE20141551A1/es active IP Right Grant
- 2012-09-26 AU AU2012316052A patent/AU2012316052A1/en not_active Abandoned
- 2012-09-26 PE PE2018001106A patent/PE20181159A1/es unknown
- 2012-09-26 ES ES17201957T patent/ES2895080T3/es active Active
- 2012-09-26 IN IN2043DEN2014 patent/IN2014DN02043A/en unknown
- 2012-09-26 CN CN201280057789.3A patent/CN103945871B/zh active Active
- 2012-09-26 HU HUE12768999A patent/HUE039857T2/hu unknown
- 2012-09-26 CU CUP2015000171A patent/CU24314B1/es unknown
- 2012-09-26 SG SG11201400538QA patent/SG11201400538QA/en unknown
- 2012-09-26 BR BR112014007069-5A patent/BR112014007069B1/pt active IP Right Grant
- 2012-09-26 AP AP2014007543A patent/AP2014007543A0/xx unknown
- 2012-09-26 PT PT12768999T patent/PT2760475T/pt unknown
- 2012-09-26 MX MX2014003677A patent/MX350273B/es active IP Right Grant
- 2012-09-26 PL PL17201957T patent/PL3321276T3/pl unknown
- 2012-09-26 PL PL12768999T patent/PL2760475T3/pl unknown
- 2012-09-26 RS RS20181146A patent/RS57868B1/sr unknown
- 2012-09-26 SI SI201231391T patent/SI2760475T1/sl unknown
- 2012-09-26 SI SI201231952T patent/SI3321276T1/sl unknown
- 2012-09-26 UA UAA201402419A patent/UA113856C2/uk unknown
-
2014
- 2014-03-07 ZA ZA2014/01700A patent/ZA201401700B/en unknown
- 2014-03-12 TN TNP2014000109A patent/TN2014000109A1/en unknown
- 2014-03-13 MA MA36824A patent/MA35437B1/fr unknown
- 2014-03-13 IL IL231533A patent/IL231533B/en active IP Right Grant
- 2014-03-25 CL CL2014000736A patent/CL2014000736A1/es unknown
- 2014-03-26 GT GT201400055A patent/GT201400055A/es unknown
- 2014-03-26 CO CO14064516A patent/CO6920257A2/es unknown
- 2014-03-26 CR CR20140140A patent/CR20140140A/es unknown
- 2014-03-26 CU CUP2014000034A patent/CU24206B1/es active IP Right Grant
- 2014-09-30 HK HK18110595.8A patent/HK1251238A1/zh unknown
-
2015
- 2015-02-24 US US14/630,206 patent/US9266935B2/en active Active
-
2016
- 2016-01-04 US US14/987,338 patent/US10076554B2/en active Active
- 2016-09-02 CL CL2016002215A patent/CL2016002215A1/es unknown
-
2017
- 2017-07-28 JP JP2017146984A patent/JP6567613B2/ja active Active
-
2018
- 2018-08-30 US US16/117,960 patent/US11129874B2/en active Active
- 2018-09-28 HR HRP20181558TT patent/HRP20181558T1/hr unknown
- 2018-10-03 CY CY181101017T patent/CY1120928T1/el unknown
-
2019
- 2019-07-31 JP JP2019141242A patent/JP2020007314A/ja not_active Withdrawn
-
2021
- 2021-03-08 UY UY0001039119A patent/UY39119A/es not_active Application Discontinuation
- 2021-08-24 US US17/410,307 patent/US11944664B2/en active Active
- 2021-10-06 CY CY20211100868T patent/CY1124697T1/el unknown
- 2021-10-25 AR ARP210102949A patent/AR123908A2/es unknown
-
2022
- 2022-01-11 JP JP2022002030A patent/JP7339372B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR123908A2 (es) | Proteínas de fusión para tratar trastorno metabólicos | |
PE20141727A1 (es) | Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas | |
CR20130234A (es) | Métodos de tratamiento de trastornos asociados con el fgf21 | |
PE20190352A1 (es) | Proteinas de fusion gdf 15 y usos de estas | |
EA201590525A1 (ru) | Слитые белки для лечения метаболического синдрома | |
MX2021006856A (es) | Uso de un peptido para modular la homeostasis de los acidos biliares o tratamiento de una enfermedad relacionada con los acidos biliares. | |
PE20130648A1 (es) | Tratamiento del sindrome de sanfilippo tipo b | |
AR092076A1 (es) | Proteinas homodimericas | |
IN2014DN09815A (es) | ||
AR093903A1 (es) | Coagonistas de glucagon y glp-1 para el tratamiento de la obesidad | |
BR112014007675A2 (pt) | tratamento de doença articular degenerativa | |
MX2012007416A (es) | Composiciones y metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis. | |
IN2014CN04498A (es) | ||
MX339203B (es) | Proteina de fusion anticancer. | |
EA201100071A1 (ru) | Новые композиции и способы | |
NZ708091A (en) | Stabilized insulin-like growth factor polypeptides | |
PE20160877A1 (es) | Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion | |
WO2015108856A3 (en) | Methods for enhancing the delivery of active agents | |
ES2421885T3 (es) | Polipéptidos y procedimiento para la detección específica de anticuerpos en pacientes con una infección por Borrelia | |
EA201400959A1 (ru) | Полученная из остеопротегерина композиция и ее применение | |
TN2013000211A1 (en) | Methods of treating fgf 21- associated disorders | |
TH8814C3 (th) | โปรตีนไฟโบรอินรีคอมบิแนนท์-อาร์จีดี | |
ATE484520T1 (de) | Antitumorheilmittel, medikament, zusammensetzung und verwendung davon |